Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device

Chen, Jessica S. BS
Adelman, Ron A. MD, MPH, MBA, FACS

From Yale School of Medicine, New Haven, CT.

Preliminary results were presented at ARVO 2015 in Denver, CO, and read on May 4, 2015.

The authors report no relevant financial disclosures.

Address correspondence to Jessica S. Chen, BS, 123 York Street, Apt. 3G, New Haven, CT 06511; email: [email protected].

Received April 07, 2016

Accepted May 26, 2016

Ophthalmic Surgery, Lasers, and Imaging Retina 47(8):p 708-715, August 01, 2016. | DOI: 10.3928/23258160-20160808-03

BACKGROUND AND OBJECTIVE:

Timely treatment of age-related macular degeneration (AMD) is integral in improving outcomes. To catch choroidal neovascularization as soon as possible, patients should monitor vision at home. The objective of this study is to explore the Hyperacuity App (HAC) as a screen for progression of disease in AMD.

PATIENTS AND METHODS:

A cross-sectional, single-center study was performed with 33 subjects. Consent was obtained and patient information was protected in accordance with the protocol approved by the Yale Human Research Protection Program. A masked retinal subspecialist then graded the spectral-domain optical coherence tomography (SD-OCT) taken the same day to determine which patients required treatment. Further data about the patient were obtained through chart review.

RESULTS:

The HAC was shown to have 92.3% sensitivity and 61.5% specificity in distinguishing between patients who required treatment and those who did not require treatment.

CONCLUSION:

The HAC is a potential screen for choroidal neovascularization in AMD.

[Ophthalmic Surg Lasers Imaging Retina. 2016;47:708–715.]